Cancer Stem Cell News Volume 8.44 | Nov 13 2019

TOP STORY

4-Hydroxy-7-Oxo-5-Heptenoic Acid Lactone Is a Potent Inducer of Brain Cancer Cell Invasiveness that May Contribute to the Failure of Anti-Angiogenic Therapies

Scientists found that low micromolar concentrations of 4-hydroxy-7-oxo-5-heptenoic acid lactone increased the cell migration velocity of cultured glioblastoma multiforme CSCs, and induced the expression of matrix metalloproteinase 1 and two protein biomarkers of the proneural to mesenchymal transition: p65 NF-κβ and vimentin. [Free Radic Biol Med] Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

Three-Dimensional Biomimetic Hyaluronic Acid Hydrogels to Investigate Glioblastoma Stem Cell Behaviors

The authors demonstrated that hyaluronic acid hydrogels can support long-term glioblastoma stem cell culture (up to 60 days) with retention of stemness markers. [Biotechnol Bioeng] Abstract

Retinoid Receptor Turnover Mediated by Sumoylation, Ubiquitination and the Valosin-Containing Protein Is Disrupted in Glioblastoma

Investigators revealed that all trans retinoic acid induced valosin-containing protein expression, creating a positive feedback loop that enhanced degradation. In contrast, the pathway was impaired in the glioma stem-like cells resulting in the accumulation of sumoylated and high molecular weight forms of retinoid receptors that lacked transcriptional activity and failed to be recognized by the proteasome. [Sci Rep] Full Article

Osteosarcoma-Initiating Cells Show High Aerobic Glycolysis and Attenuation of Oxidative Phosphorylation Mediated by LIN28B

The authors characterized sarcoma-initiating cells (SICs) of a novel osteosarcoma (OS) cell line, screened for SICs-related genes, and tried to regulate the proliferation of OS by metabolic interference. [Cancer Sci] Abstract

Exosomes Derived from Cancer Stem Cells of Gemcitabine-Resistant Pancreatic Cancer Cells Enhance Drug Resistance by Delivering miR-210

BxR-CSC-derived exosomes induced gemcitabine (GEM) resistance, inhibited GEM-induced cell cycle arrest, antagonized GEM-induced apoptosis, and promoted tube formation and cell migration in BxS and PANC-1 cells. [Cell Oncol (Dordr)] Full Article

Ring1 Promotes the Transformation of Hepatic Progenitor Cells into Cancer Stem Cells through the Wnt/β-Catenin Signaling Pathway

The activation of the Wnt/β-catenin signaling pathway significantly increased the expression of liver cancer stem cells related (LCSCs)-related molecular markers CD90 and EpCAM, which led to the transformation of hepatic progenitor cells into LCSCs. [J Cell Biochem] Abstract

Protective and Anticancer Effects of Orange Peel Extract and Naringin in Doxorubicin Treated Esophageal Cancer Stem Cell Xenograft Tumor Mouse Model

Orange peel extract could protect the cellular toxicity of doxorubicin in vitro mainly by decreasing cellular apoptosis of ESCC CSCs. However, S-phase cell cycle arrest was not affected significantly. [Biomed Pharmacother] Abstract

Application of RNA-Sequencing to Identify Transcriptome Modification by DCLK1 in Colorectal Cancer Cells

Scientists applied RNA-Sequencing technology, a high throughput massively next-generation sequencing approach, to monitor transcriptome changes due to doublecortin-like kinase 1 (DCLK1) overexpression in the colorectal cancer cells. [Cancer Gene Ther] Abstract

MTA3 Represses Cancer Stemness by Targeting the SOX2OT/SOX2 Axis

By forming a repressive complex with GATA3, MTA3 downregulated SOX2OT, subsequently suppressed the SOX2OT/SOX2 axis and ultimately repressed cancer cell stemness and metastasis. [iScience] Abstract | Full Article | Graphical Abstract

Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News.

Cancer Stem Cells as Therapeutic Targets of Pancreatic Cancer

The authors describe CSC characteristics in general, while also focusing on CSC properties in the context of pancreatic cancer. [Fundam Clin Pharmacol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase II Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

AVEO Oncology and Biodesix, Inc. announced the initiation of the CyFi-2 study, a randomized Phase II clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). [AVEO Oncology] Press Release

Janssen Announces Submission of Supplemental New Drug Application to US FDA Seeking Approval of IMBRUVICA^® (Ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental New Drug Application to the US FDA seeking approval to expand the IMBRUVICA^® label to include the combination with rituximab for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [The Janssen Pharmaceutical Companies of Johnson & Johnson] Press Release

AB8939 Receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA

AB Science SA announces that the FDA has granted the company Orphan Drug designation for compound AB8939 in the treatment of acute myeloid leukemia. [AB Science SA] Press Release

More South Korean Academics Caught Naming Kids as Co-Authors

The number of South Korean academics accused of naming children as co-authors on research manuscripts — even though the children did not contribute to the research — continues to grow. [Nature News] Editorial

What the Protests and Violence in Chile Mean for Science

As universities shut down, researchers are demonstrating — and meeting with lawmakers to figure out if science can help solve socio-economic inequality. [Nature News] Editorial

NEW Advances in Stem Cells and Regenerative Medicine
March 8-11, 2020
Heidelberg, Germany

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Leukemia (University Hospital of Muenster)

Postdoctoral Studentships – Stem Cell Biology (University of Oxford)

Postdoctoral Position – Immune-targeting of Leukemic Stem Cells (Karolinska Institutet)

Postdoctoral Studentship – HOX Interactors for Leukemia (University of Manchester)

Faculty Positions – Molecular and Cellular Biology (Baylor College of Medicine)

Postdoctoral Scholar – Cancer Biology (University of Kentucky)

Postdoctoral Position – Cellular Immunotherapy for Cancer (Tactiva Therapeutics)

Postdoctoral Position – Cancer Biology (Weill Cornell Medicine)

Assistant, Associate, or Professor – Hematology (Stanford University)

Assistant, Associate or Professor – Oncological Sciences (University of Utah)

Postdoctoral Researcher – Cancer Stem Cells in Glioblastoma (The Institut Curie Research Center)

Postdoctoral Associate – Hematopoietic Stem Cells and Leukemia (The Jackson Laboratory)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.